review article | Q7318358 |
scholarly article | Q13442814 |
editorial | Q871232 |
P2093 | author name string | E Nobile-Orazio | |
P2860 | cites work | Different ceramide compositions of gangliosides between human motor and sensory nerves | Q28331409 |
Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies | Q28334663 | ||
Multifocal motor neuropathy with conduction block: a study of 24 patients | Q33734400 | ||
Multifocal motor neuropathy: response to human immune globulin | Q34062007 | ||
Manipulating the Immune System with Immune Globulin | Q36725772 | ||
Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study | Q36880697 | ||
Separating motor neuron diseases from pure motor neuropathies. Multifocal motor neuropathy with persistent conduction block | Q37185303 | ||
Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I. | Q40571159 | ||
The clinical and diagnostic role of anti-GM1 antibody testing | Q40792321 | ||
Do GM1 antibodies induce demyelination? | Q40792325 | ||
Antiganglioside antibodies do not necessarily play a role in multifocal motor neuropathy | Q40792349 | ||
Chronic motor neuropathies: diagnosis, therapy, and pathogenesis | Q41270462 | ||
Clinical and neurophysiological assessment of immunoglobulin therapy in five patients with multifocal motor neuropathy | Q41663344 | ||
Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin | Q41766911 | ||
The pathological basis of conduction block in human neuropathies | Q42159032 | ||
Antiglycolipid antibodies in peripheral neuropathy: fact or fiction? | Q42714089 | ||
Multifocal motor neuropathy with conduction block: is it a distinct clinical entity? | Q43583532 | ||
Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease | Q43839016 | ||
A computer simulation of conduction block: effects produced by actual block versus interphase cancellation | Q43871919 | ||
A syndrome of asymmetric limb weakness with motor conduction block | Q44992268 | ||
Motor neuron disease in a patient with a monoclonal IgMk directed against GM1, GD1b, and high-molecular-weight neural-specific glycoproteins | Q47444101 | ||
Acute conduction block in vitro following exposure to antiganglioside sera. | Q51662994 | ||
High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. | Q53771496 | ||
Motor Neuropathy with Proximal Multifocal Persistent Conduction Block, Fasciculations and Myokymia | Q56608957 | ||
Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies | Q59389262 | ||
Neuropathy with onion bulb formations and pure motor manifestations | Q62803885 | ||
Polyclonal IgM anti-GM1 ganglioside antibody in patients with motor neuron disease and variants | Q67301312 | ||
Intravenous immunoglobulin for multifocal motor neuropathy | Q67521954 | ||
Motor neuropathy with multifocal persistent conduction blocks | Q68035750 | ||
Clinical correlations of anti-GM1 antibodies in amyotrophic lateral sclerosis and neuropathies | Q68048629 | ||
Immunosuppressive treatment in multifocal motor neuropathy | Q68060632 | ||
Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy | Q68075974 | ||
Experimental conduction block induced by serum from a patient with anti-GM1 antibodies | Q68125702 | ||
IgM deposits at nodes of Ranvier in a patient with amyotrophic lateral sclerosis, anti-GM1 antibodies, and multifocal motor conduction block | Q68396033 | ||
The spectrum of neurologic disease associated with anti-GM1 antibodies | Q68464279 | ||
Lower motor neuron disease in a patient with autoantibodies against Gal(beta 1-3)GalNAc in gangliosides GM1 and GD1b: improvement following immunotherapy | Q68762777 | ||
Monoclonal IgM with unique specificity to gangliosides GM1 and GD1b and to lacto-N-tetraose associated with human motor neuron disease | Q69025264 | ||
Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome | Q69599049 | ||
Motor neuropathy with multifocal conduction blocks | Q69656919 | ||
A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside | Q69836574 | ||
Chronic multifocal demyelinating neuropathy simulating motor neuron disease | Q70136327 | ||
Predictive value of anti-GM1 ganglioside antibodies in neuromuscular diseases: a study of 180 sera | Q70155304 | ||
Pathological findings at the site of conduction block in multifocal motor neuropathy | Q70564756 | ||
Multifocal demyelinating neuropathy with persistent conduction block | Q70680262 | ||
Multifocal demyelinating motor neuropathy: pathologic evidence of 'inflammatory demyelinating polyradiculoneuropathy' | Q71525397 | ||
Diagnostic value of GM 1 antibodies in motor neuron disorders and neuropathies | Q71980862 | ||
Clinical and electrophysiologic correlates of elevated anti-GM1 antibody titers | Q72071749 | ||
Failure of anti-GM1 IgG or IgM to induce conduction block following intraneural transfer | Q72153374 | ||
Multifocal motor neuropathy: electrodiagnostic features | Q72258848 | ||
Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study | Q72335038 | ||
Cloning of human anti-GM1 antibodies from motor neuropathy patients | Q72356052 | ||
Progression of multifocal motor neuropathy during apparently successful treatment with human immunoglobulin | Q72437091 | ||
Multifocal motor neuropathy or CIDP? | Q72605913 | ||
Immunosuppressive treatment of motor neuron syndromes. Attempts to distinguish a treatable disorder | Q72765673 | ||
Immunosuppressive treatment in lower motor neuron syndrome with autoantibodies against GM1 ganglioside | Q72770824 | ||
Distal lower motor neuron syndrome with high-titer serum IgM anti-GM1 antibodies: improvement following immunotherapy with monthly plasma exchange and intravenous cyclophosphamide | Q72829528 | ||
Persistent and transient "conduction block" in motor neuron diseases | Q72890170 | ||
Delayed rectifier current of bullfrog sympathetic neurons: ion-ion competition, asymmetrical block and effects of ions on gating | Q73175906 | ||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 599-603 | |
P577 | publication date | 1996-06-01 | |
P1433 | published in | Journal of Neurology, Neurosurgery and Psychiatry | Q1599804 |
P1476 | title | Multifocal motor neuropathy | |
P478 | volume | 60 |
Q73739726 | 79(th) ENMC International Workshop: multifocal motor neuropathy. 14-15 April 2000, Hilversum, The Netherlands |
Q40946779 | Anti-GM2 IgM antibodies: clinical correlates and reactivity with a human neuroblastoma cell line. |
Q35470170 | Central motor conduction in patients with anti-ganglioside antibody associated neuropathy syndromes and hyperreflexia |
Q74452603 | Chronic motor axonal neuropathy: pathological evidence of inflammatory polyradiculoneuropathy |
Q77676374 | Early diagnosis of ALS/MND |
Q50778320 | Epidemiology and characteristics of Guillain-Barré syndrome in the northwest of Iran. |
Q33735651 | Epidemiology of peripheral neuropathy |
Q50969853 | Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. |
Q40866049 | Intravenous immunoglobulin treatment of neurological autoimmune diseases |
Q36317538 | Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy |
Q34510425 | Medical technology assessment. Electrodiagnosis in motor neuron diseases and amyotrophic lateral sclerosis. |
Q72997223 | Monofocal motor neuropathy responsive to intravenous immunoglobulins |
Q43111229 | Motor-dominant chronic inflammatory demyelinating polyneuropathy. |
Q81679400 | Multifocal motor neuropathy |
Q34204618 | Multifocal motor neuropathy. |
Q36318744 | Single fibre electromyography in multifocal motor neuropathy with persistent conduction blocks |
Q80880304 | [Multifocal motor neuropathy with persistent conduction blocks: 18 years on] |
Search more.